A phase 1 dose escalating study of ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours
ACTRN 12618001070224 Brief Summary This is a Phase I, open-label, single arm,…
Read more arrow_forwardACTRN 12618001070224 Brief Summary This is a Phase I, open-label, single arm,…
Read more arrow_forwardNCT 07121244 Brief Summary A phase 1 study of 68Ga-R11228 and 177Lu-R11228…
Read more arrow_forwardNCT 07016490 Brief Summary This study is an open-label phase I study…
Read more arrow_forwardNCT 06533332 Brief Summary This is a Phase 1 study to assess…
Read more arrow_forwardNCT 06956690 Brief Summary This study is a Phase 1/2, first-in-human, open-label,…
Read more arrow_forwardNCT 05914116 Brief Summary This is a dose-escalation and dose-expansion Phase 1/2a…
Read more arrow_forwardACTRN 12622000993796 Brief Summary AXA-042 functions through a multi-cellular mechanism to re-engage…
Read more arrow_forwardACTRN 12623000956606 Brief Summary This study will be conducted in two parts…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardACTRN 12620000592943 Brief Summary This purpose of this study is to determine…
Read more arrow_forward